➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
Baxter
AstraZeneca
Express Scripts
Harvard Business School
Dow

Last Updated: October 16, 2021

DrugPatentWatch Database Preview

Bacillus anthracis - Biologic Drug Details


Email this page to a colleague

« Back to Dashboard

Recent Clinical Trials for bacillus anthracis

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Kafrelsheikh UniversityPhase 2
Damietta UniversityPhase 2
BayerN/A

See all bacillus anthracis clinical trials

Recent Litigation for bacillus anthracis

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
MEDIZONE INTERNATIONAL, INC.2018-05-08
XtraLight Manufacturing, Ltd.2018-04-11
NYU Winthrop Hospital v. Microbion Corporation2017-10-20

See all bacillus anthracis litigation

PTAB Litigation
PetitionerDate
2018-07-27

See all bacillus anthracis litigation

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. General brand-side disclosures
  4. These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for bacillus anthracis Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for bacillus anthracis Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for bacillus anthracis Derived from Patent Text Search

These patents were identified by searching patent claims

Supplementary Protection Certificates for bacillus anthracis

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
19010 Norway ⤷  Free Forever Trial PRODUCT NAME: ERAVASYKLIN ELLER FARMASOEYTISK AKSEPTABLE SALTER DERAV; REG. NO/DATE: EU/1/18/1312 20181025
C1012 France ⤷  Free Forever Trial PRODUCT NAME: ERAVACYCLINE OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/18/1312 20180924
19/013 Ireland ⤷  Free Forever Trial PRODUCT NAME: ERAVACYCLINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; NAT REGISTRATION NO/DATE: EU/1/18/1312 20180920
C00107 Luxembourg ⤷  Free Forever Trial PRODUCT NAME: ERAVACYCLINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/18/1312 20180924
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Mallinckrodt
Boehringer Ingelheim
Moodys
McKesson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.